Cancer

Treatment Versus No Treatment of Localized Prostate Cancer Had Similar Results Over 15 Years, 1 Question Raised

Treatment Versus No Treatment of Localized Prostate Cancer Had Similar Results Over 15 Years, 1 Question Raised
Kateryna Kon/Shutterstock
Yuwei Zhang, M.D., Ph.D.
&
Conna Craig
|Updated:
0:00

Every cancer diagnosis comes with a range of reactions, including the natural inclination to act as quickly as possible to choose and begin treatment.

However, a new study has revealed that, in the case of prostate cancer, over 15 years, outcomes were surprisingly similar for three groups: a prostatectomy group, a radiotherapy group, and a nontreatment group under active monitoring. The study’s authors found that prostate cancer-specific mortality was relatively low regardless of the approach taken.

The Clinical Trial

The new findings are based on 15-year outcomes of the Prostate Testing for Cancer and Treatment (ProtecT) clinical trial sponsored by the University of Oxford. This long-term trial was initiated in 2001 and will continue until 2027.
Yuwei Zhang, M.D., Ph.D., MPH, MBA, has 20 years of experience in oncology and healthcare, including work for providers, payers, and pharma companies. Her paper on esophageal cancer is one of the top ten most cited papers in the field. She regularly gives talks at universities, has been invited to review manuscripts for top-tier medical journals, and has supported successful launches of top-performing drugs with expertise in lifecycle management, data strategy, and digital innovation.
Related Topics